Clinical Trials Logo

Clinical Trial Summary

Fabry Disease (FD) is a rare lysosomal storage disorder due to the absence or deficiency of hydrolase α-galactosidase A (α-Gal A) activity in lysosomes. This dysfunction results in progressive accumulation of glycosphingolipids in a wide variety of cells, resulting in major organ system damage. Patients with Fabry disease can suffer from neuropathic pain, since lysosomal accumulation affects small unmyelinated nerve fibers. Neuropathic pain is one of the prominent and debilitating symptoms significantly interfering with life quality in FD patients. Current treatment of Fabry patients with neuropathic pain is deficient, as they respond poorly to a conventional pain therapy, often require a high-dose opioids treatment and presentation to the Emergency Department. Sativex® has been shown to be a successful treatment option in neuropathic pain of different origin with minimal neuropsychological influence: in multiple sclerosis (MS), chemotherapy-induced neuropathic pain and other. It contains Δ-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) and has recently been licensed in Switzerland for treatment of neuropathic chronic pain in MS. Sativex® is an oral spray.


Clinical Trial Description

Fabry disease is an X-linked lysosomal storage disease caused by a deficiency of the enzyme α-galactosidase A. Patients suffering from Fabry's disease may suffer from neuropathic pain, since the lysosomal accumulation of lipids can also take place in the small nerve fibers. Typically, neuropathic pain occurs in late childhood or adolescence and disappears after several years, probably due to the irreversible destruction of the small nerve fibers. The pain management of Fabry patients suffering from neuropathic pain is inadequate, as patients often do not respond well to conventional pain therapies. Aim of this study: The aim of this study is to find out how strongly the investigational drug Sativex® (active ingredients: tetrahydrocannabinol (THC) and cannabidiol (CBD)) can influence the pain that can be caused by Fabry's disease. For this purpose, the investigational drug is compared with a placebo drug. The latter is a drug without an active ingredient. These studies provide us with important information on the origin of the pain and at the same time on the mechanism of action of Sativex®. This makes it possible to develop new forms of therapy in the future. Procedure: A total of 22-30 patients are divided into two groups of 11-15 patients each. Both groups will undergo the same test program. This will be divided into two phases: In the first phase, which will last 8 weeks, one group will receive Sativex® while the other group will receive a placebo. In the second phase, which will also last 8 weeks, the group that previously received the investigational drug will now receive the placebo and the previous placebo group will now receive the investigational drug. The study is double-blind, i.e. neither the patient nor the investigator knows who is receiving the investigational drug or the placebo. Patients are randomly assigned to the groups. Throughout the treatment, patients maintain their usual pain management regimen. (see Study Schedule) For 14 weeks, patients will fill out their pain diary daily. Every two weeks a blood sample is taken to determine the levels of cannabinoid metabolites. At the beginning, at the end of the first and after the second phase, the patient will fill out various questionnaires on neuropathic pain and improvement of quality of life. This will be used to assess whether pain relief is achieved. Translated with www.DeepL.com/Translator (free version) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04820361
Study type Interventional
Source University of Zurich
Contact Albina Nowak, PD
Phone +41432538872
Email albina.nowak@usz.ch
Status Recruiting
Phase N/A
Start date July 7, 2022
Completion date December 29, 2023

See also
  Status Clinical Trial Phase
Completed NCT03244540 - Regional Analgesia After Cesarean Section Phase 4
Completed NCT04080037 - Assessing Opioid Care Practices Using CPV Patient Simulation Modules N/A
Completed NCT03280017 - Ketamine With Multilevel Paravertebral Block for Post Video-assisted Thoracic Surgery Pain Phase 4
Enrolling by invitation NCT04097015 - Using NI-ES to Treat Spinal Cord Injury (SCI) N/A
Not yet recruiting NCT04585620 - Botulinum Toxin A as Treatment for Chronic Postsurgical Pain Following Lung Cancer Surgery Phase 1/Phase 2
Completed NCT04371575 - Symptomatic Trigeminal Neuralgia Attributed to Multiple Sclerosis - a Prospective Study in 60 Patients
Completed NCT03723447 - Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®) Phase 4
Completed NCT01485185 - Gabapentin and Donepezil Combination on Experimental Human Pain Models Phase 1
Completed NCT04375436 - Safety and Tolerability of NTRX-07 in Healthy Volunteers Phase 1
Terminated NCT03691038 - Comparison of Conventional Dose Regimen and New Dose Regimen of Pregabalin N/A
Completed NCT03674489 - Local and Widespread Hypoalgesic Effects of Neurodynamic Mobilization in Healthy Controls N/A
Recruiting NCT04299893 - Ozone Therapy in Chemotherapy-induced Peripheral Neuropathy: RCT (O3NPIQ) Phase 2/Phase 3
Recruiting NCT03618589 - Pregabalin add-on for Neuropathic Pain in Cervical Myelopathy Phase 1
Completed NCT04625504 - Investigating Biological Targets, Markers, and Intervention for Chronic Pain N/A
Recruiting NCT04622904 - Lidocaine and Magnesium and Ketamine in Gynecological Surgery N/A
Recruiting NCT06062108 - Prevalence of Pain in Hospitalized Cirrhotic Patients
Recruiting NCT04718116 - Tapentadol Versus Tramadol Analgesia Post Cardiac Surgery N/A
Recruiting NCT04909593 - Study to Evaluate Automated Intensity Management in Patients Undergoing a BSC SCS Temporary Trial N/A
Recruiting NCT05243940 - Opioid-free Anesthesia in Thyroidectomies N/A
Recruiting NCT05349448 - Can Dexmedetomidine With Hyalase Augment Quality and Duration of Analgesia When Added to Lumbar Epidural Steroid in Failed Back Surgery. Randomized Double Blind Study Early Phase 1